http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113244400-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P41-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2021-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113244400-B |
| titleOfInvention | Application of a C5aRA in the preparation of products for treating and/or preventing abdominal adhesions |
| abstract | The invention discloses an application of C5aRA in the preparation of products for treating and/or preventing abdominal adhesions, and relates to the field of medical biotechnology; the invention discloses an application of C5aRA in preparing products for treating and/or preventing abdominal adhesions, namely The new application of C5aRA; the present invention finds through research, C5aRA can maintain the form of RPMCs, human peritoneal mesothelial cells, improve the activity of the form of RPMCs, human peritoneal mesothelial cells; therefore, C5aRA can protect damaged mesothelial cells, and Can inhibit the EMT process of mesothelial cells. At the same time, C5aRA can down-regulate α-SMA, TGF-β1, and OPN, that is, C5aRA can also reduce tissue inflammation and inhibit fibrosis to improve peritoneal adhesions. |
| priorityDate | 2021-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 103.